Purified c5a receptor from human polymorphonuclear leukocytes.
CA 2006955 A1 · Owner: Rollins, Thomas E. · Inventors: Springer, Martin S.; Rollins, Thomas E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
TITLE OF THE INVENTION, PURIFIED C5a RECEPTOR FROM HUMAN POLYMORPHONUCLEAR LEUKOCYTES, ABSTRACT OF THE DISCLOSURE A method is disclosed for isolating and purifying C5a receptor from human polymorphonuclear leukocytes. C5a is a complement-derived protein which is important as a mediator of inflammatory responses. C5a receptor may be used to screen create and quantify C5a antagonists useful as anti-inflammatory agents and immunoregulants and to generate monoclonal and polyclonal anti-C5a receptor antibodies useful as anti-inflammatory agents and immunoregulants.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 29, 1989. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 29, 2009.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 29, 2011.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.